Lisata Therapeutics, Inc. · NASDAQ:LSTA

Lisata Therapeutics — Marea Therapeutics — Investor Presentation (November 2026)

22 slides from Lisata Therapeutics's investor presentation, November 2026

  1. Slide 1: Marea Therapeutics: Transformative cardioendocrine therapies

    Slide 1: Marea Therapeutics: Transformative cardioendocrine therapies

    November 2026 Marea Therapeutics Transformative cardioendocrine therapies ©2023 Marea Therapeutics 1

  2. Slide 2: Forward Looking Statements & Disclaimers

    Slide 2: Forward Looking Statements & Disclaimers

    Forward Looking Statements & Disclaimers This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding Marea Therapeutics, Inc.’s (“Marea,” the “Company,” “we,” “us” or “our”) research, preclinical and clinical development activities, pl

  3. Slide 3: Two Clinical Assets Target Large, Underserved Cardioendocrine Markets

    Slide 3: Two Clinical Assets Target Large, Underserved Cardioendocrine Markets

    Two Clinical Assets Target Large, Underserved Cardioendocrine Markets Two differentiated programs: MAR001/5 in a >$10B sHTG market; MAR002 in a >$1.4B acromegaly market Patient need Clinical Activity Differentiation Opportunity MAR001/5 Severe Hypertriglyceridemia >3M Matches APOC32 Clean metabolic

  4. Slide 4: Late-stage Cardioendocrine Pipeline with Multiple 2026–27 Readouts

    Slide 4: Late-stage Cardioendocrine Pipeline with Multiple 2026–27 Readouts

    Late-stage Cardioendocrine Pipeline with Multiple 2026–27 Readouts Molecule Target Indication Disc IND-E Ph1 Ph2 Ph3 Anticipated Near-term Milestones MAR001 Ph2b TYDAL (mHTG/sHTG) Q2 2026 ✓ • Phase 2b TYDAL Part A 12-week data Cardiometabolic H2 2026 ✓ • Phase 2b TYDAL Part A 24-week data MAR001 ANG

  5. Slide 5: MAR005 for sHTG

    Slide 5: MAR005 for sHTG

    MAR005 for sHTG Potent sHTG candidate with a clean metabolic profile ©2023 Marea Therapeutics 5

  6. Slide 6: sHTG Is a Large Unmet Need Validated by APOC3 Inhibitors

    Slide 6: sHTG Is a Large Unmet Need Validated by APOC3 Inhibitors

    sHTG Is a Large Unmet Need Validated by APOC3 Inhibitors APOC3 drugs cut TG 60–80% and pancreatitis events 78–85%, opening a >$10B US market The unmet need APOC3 inhibitors validate the opportunity US adults with sHTG TG reduction from baseline >3M • 1M at high risk of recurrent acute pancreatitis1

  7. Slide 7: APOC3 Class Efficacy Comes at a Cost: HbA1c Increases in Patients with T2DM

    Slide 7: APOC3 Class Efficacy Comes at a Cost: HbA1c Increases in Patients with T2DM

    APOC3 Class Efficacy Comes at a Cost: HbA1c Increases in Patients with T2DM Placebo-corrected TG down 46 to 65%, yet HbA1c rises 0.25 to 0.36 pts vs. placebo in T2DM Placebo-corrected Change from baseline 80% 80% Additional safety signals 71% 63% Glycemic AEs 60% TG 65% Plozasiran: worsening glycemi

  8. Slide 8: Biology and Genetics Support ANGPTL4 Inhibition as Potential Best-in-Disease Profile

    Slide 8: Biology and Genetics Support ANGPTL4 Inhibition as Potential Best-in-Disease Profile

    Biology and Genetics Support ANGPTL4 Inhibition as Potential Best-in-Disease Profile TG disposal into fat, not liver ANGPTL4 inhibition (MAR001/5) APOC3 inhibition (olezarsen / plozasiran) TG routed to the liver TG cleared into fat • Speeds liver uptake of TG • Unblocks LPL in adipose remnants TG ti

  9. Slide 9: TYDAL-TIMI Phase 2b: Potent TG Lowering without Safety, Tolerability or HbA1c Signals

    Slide 9: TYDAL-TIMI Phase 2b: Potent TG Lowering without Safety, Tolerability or HbA1c Signals

    TYDAL-TIMI 78 Phase 2b: Potent TG Lowering without Safety, Tolerability or HbA1c Signals Primary endpoint met at every dose (P<0.001); larger effect at higher baseline TG Study design Change from baseline Placebo-adjusted 235 patients · 44% T2DM Baseline TG 150–880 mg/dL All patients Placebo +5%; al

  10. Slide 10: Reduction Scales with Baseline Triglycerides: Rises from 38% to 71%

    Slide 10: Reduction Scales with Baseline Triglycerides: Rises from 38% to 71%

    Reduction Scales with Baseline Triglycerides: Rises from 38% to 71% Every sHTG patient on 450 or 900 mg reduced TGs 61 to 80% at Week 12 % change in TG from baseline, by baseline TG group TG ≥500 mg/dL: each patient on 450 or 900 mg (n=6) MAR001 450 + 900 mg, from baseline Placebo +20% 0% +5% +7% 0%

  11. Slide 11: MAR001: Potential Best-in-Disease Profile

    Slide 11: MAR001: Potential Best-in-Disease Profile

    MAR001: Potential Best-in-Disease Profile Similar TG reduction; no HbA1c increase in T2DM Placebo response grows with trial length; Placebo-corrected Change from baseline compare dark bars. MAR001 Safety profile to date 80% 80% 71% 71% Glycemic markers 63% • no adverse change in HbA1c, TG 60% fastin

  12. Slide 12: MAR005 Is Designed for the Majority of sHTG Patients Who Also Have Diabetes

    Slide 12: MAR005 Is Designed for the Majority of sHTG Patients Who Also Have Diabetes

    MAR005 Is Designed for the Majority of sHTG Patients Who Also Have Diabetes Glycemic neutrality: clinically meaningful, valued by physicians, large opportunity 0.3% #1 1.8M HbA1c rise matters in T2DM Physician-weighted attribute US sHTG patients with T2DM Clinically meaningful: confers for new sHTG

  13. Slide 13: TYDAL-TIMI Part B: Confirming Effects in sHTG; Next Data Catalyst

    Slide 13: TYDAL-TIMI Part B: Confirming Effects in sHTG; Next Data Catalyst

    TYDAL-TIMI 78 Part B: Confirming Effects in sHTG; Next Data Catalyst ~100 patients with TG ≥500 mg/dL randomized to MAR001 600 mg vs placebo; topline H2 2027 Study design Study Goals ~100 patients, nonfasting TG ≥500 and fasting TG ≥450 mg/dL ~50% T2DM enrichment Strong TG drop Day 1 Week 12 Week 24

  14. Slide 14: MAR002 for Acromegaly

    Slide 14: MAR002 for Acromegaly

    MAR002 for Acromegaly First long-acting GHR antagonist candidate for acromegaly ©2023 Marea Therapeutics 14

  15. Slide 15: Acromegaly: Serious Disease with Inadequate Options for Medical Therapy

    Slide 15: Acromegaly: Serious Disease with Inadequate Options for Medical Therapy

    Acromegaly: Serious Disease with Inadequate Options for Medical Therapy The Burden & Opportunity Two Approaches to Medical Therapy ~30K US patients Pituitary Gland • Excess GH from a benign pituitary adenoma Early mortality and high morbidity 1 Inhibit Secretion • Bone/organ overgrowth; cardiometabo

  16. Slide 16: An Optimal GHRA Could Become the Treatment of Choice for Most Acromegaly Patients

    Slide 16: An Optimal GHRA Could Become the Treatment of Choice for Most Acromegaly Patients

    An Optimal GHRA Could Become the Treatment of Choice for Most Acromegaly Patients 1. SRLs first-line for ~80% after surgery 2. >70% remain uncontrolled 3. Add or switch to a GHRA THE UNMET NEED THE OPPORTUNITY >70% of patients fail to >80% of these patients 18% uncontrolled respond to first-line res

  17. Slide 17: MAR002: A Long-Acting GHRA Built to Fix Pegvisomant's Limits

    Slide 17: MAR002: A Long-Acting GHRA Built to Fix Pegvisomant's Limits

    MAR002: A Long-Acting GHRA Built to Fix Pegvisomant's Limits MAR002 targets better control than SRLs with far less burden than pegvisomant An optimal direct GHRA could be a large opportunity Pegvisomant today MAR002 target profile Annual global sales; SRL class projected for 2033* Daily injections E

  18. Slide 18: Phase 1: Shows Deep, Durable IGF-1 Suppression and Supports Every-2-Week Dosing

    Slide 18: Phase 1: Shows Deep, Durable IGF-1 Suppression and Supports Every-2-Week Dosing

    Phase 1: Shows Deep, Durable IGF-1 Suppression and Supports Every-2-Week Dosing Mean (±SEM) % change in IGF-1 by cohort in healthy volunteers: single doses 50–900 mg and 900 mg ×3 Gray lines: lower single doses Dashed line: placebo Peak IGF-1 suppression 60% 40% 65% 900 mg ×3 in HVs vs 49% max for d

  19. Slide 19: MAR002: Emerging Data Supports Potential Best-in-Class Profile

    Slide 19: MAR002: Emerging Data Supports Potential Best-in-Class Profile

    MAR002: Emerging Data Supports Potential Best-in-Class Profile Deeper, longer IGF-1 suppression than pegvisomant in healthy volunteers, with every-2-week dosing MAR002 Pegvisomant In Vitro Potency with excess GH 90% suppression 24% suppression Peak IGF-1 suppression Healthy volunteers −64% −49% Days

  20. Slide 20: TROUGH-2 Phase 2 Will Set the Phase 3 Dose Across First- and Second-Line Patients

    Slide 20: TROUGH-2 Phase 2 Will Set the Phase 3 Dose Across First- and Second-Line Patients

    TROUGH-2 Phase 2 Will Set the Phase 3 Dose Across First- and Second-Line Patients Randomized, double-blind, placebo-controlled; every-2-week dosing; first patient dosed Sep 30, 2026 Study design Study Goals ~72 patients, active acromegaly IGF-1 ≥1.3× ULN Beat SRL IGF-1 reduction Day 1 Week 10 150 mg

  21. Slide 21: Multiple Value-Inflection Catalysts Through 2028

    Slide 21: Multiple Value-Inflection Catalysts Through 2028

    Multiple Value-Inflection Catalysts Through 2028 Two potentially first-in-class programs, both expected to be Phase 3-ready by early 2028 Mid-2027 H2 2027 H1 2028 TYDAL Part B sHTG topline MAR001 / MAR005 MAR005 Phase 3 dose selection + MAR005 Phase 3 start sHTG by end of 2027 MAR002 TROUGH-2 toplin

  22. Slide 22: Thank You

    Slide 22: Thank You

    Thank You ©2026 Marea Therapeutics, Inc. All rights reserved.

Source: company website

More decks from Lisata Therapeutics, Inc.

All 93 Lisata Therapeutics decks